Mkts

SAB Biotherapeutics, Inc.

NASDAQ: SABS
$2.53-0.06 (-2.32%)
As of Oct 16, 4:00 PM ET

Key statistics

Day range
2.472.63
52-week range
2.105.15
Today
Open2.59
Previous close2.53
Volume—
Valuation
Market cap230.20M
P/E ratio17.34×
EPS (TTM)-1.42
Income & risk
Dividend / yield—
Beta0.81
Avg volume674.9K
Discussion

SABS News

Stories mentioning SABS from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue263.00
Cost of Goods Sold
Gross Profit0.000.000.000.000.00
Operating Expenses
Research & Development13,39810,7288,9706,9977,6577,4537,8316,822
Sales General & Admin
Total Operating Expenses19,99815,77012,6799,73210,77210,12411,30910,465
Operating Income (Loss)(19,998)(15,770)(12,679)(9,732)(10,772)(10,009)(11,309)(10,202)
Interest Income
Interest Expense93.00
Other Expense
Pretax Income(10,349)(7,335)
Tax Provision
Net Income (Loss)(18,869)(16,860)45,445(10,114)(5,197)(11,395)(10,349)(7,335)
Earnings Per Share (Basic)(0.35)(0.87)0.50(1.09)(0.56)(1.23)(1.12)(0.79)
Earnings Per Share (Diluted)(0.35)(0.27)(0.21)(1.09)(0.56)(1.23)(1.12)(0.79)
Weighted Average Shares Outstanding (Basic)53,55919,31210,6619,2949,2929,2629,2599,255
Weighted Average Shares Outstanding (Diluted)53,55961,34077,8639,2949,2929,2629,2599,255

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About SABS

SAB Biotherapeutics, Inc. (NASDAQ: SABS) is a stock listed on the Nasdaq Stock Market under the ticker symbol SABS. It last traded at $2.53 (Oct 16, 2026, 4:00 PM ET), down 2.3% on the day. That gives SAB Biotherapeutics a market capitalisation of $230.2M and a price-to-earnings ratio of 17.3.

Over the past 52 weeks SABS has traded between $2.10 and $5.15.

For the quarter ended Mar 31, 2026 it reported a net loss of $18.9M.

Last 4 quarters
Quarter endedRevenueNet income
Mar 31, 2026—-$18.9M
Dec 31, 2025—-$16.9M
Sep 30, 2025—$45.4M
Jun 30, 2025—-$10.1M

From SAB Biotherapeutics’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…